PMC:7113610 / 17572-19130 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"603","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"635","span":{"begin":322,"end":337},"obj":"Gene"},{"id":"636","span":{"begin":605,"end":609},"obj":"Gene"},{"id":"637","span":{"begin":1341,"end":1345},"obj":"Gene"},{"id":"638","span":{"begin":364,"end":374},"obj":"Species"},{"id":"639","span":{"begin":391,"end":399},"obj":"Species"},{"id":"640","span":{"begin":696,"end":704},"obj":"Species"},{"id":"641","span":{"begin":898,"end":908},"obj":"Species"},{"id":"642","span":{"begin":930,"end":936},"obj":"Species"},{"id":"643","span":{"begin":941,"end":945},"obj":"Species"},{"id":"644","span":{"begin":1034,"end":1042},"obj":"Species"},{"id":"645","span":{"begin":1087,"end":1095},"obj":"Species"},{"id":"646","span":{"begin":1249,"end":1259},"obj":"Species"},{"id":"647","span":{"begin":205,"end":215},"obj":"Chemical"},{"id":"648","span":{"begin":267,"end":277},"obj":"Chemical"},{"id":"649","span":{"begin":307,"end":318},"obj":"Chemical"},{"id":"650","span":{"begin":531,"end":541},"obj":"Chemical"},{"id":"651","span":{"begin":543,"end":555},"obj":"Chemical"},{"id":"652","span":{"begin":557,"end":566},"obj":"Chemical"},{"id":"653","span":{"begin":568,"end":579},"obj":"Chemical"},{"id":"654","span":{"begin":581,"end":592},"obj":"Chemical"},{"id":"655","span":{"begin":594,"end":603},"obj":"Chemical"},{"id":"656","span":{"begin":611,"end":622},"obj":"Chemical"},{"id":"657","span":{"begin":628,"end":635},"obj":"Chemical"},{"id":"658","span":{"begin":1370,"end":1376},"obj":"Chemical"},{"id":"659","span":{"begin":520,"end":529},"obj":"Disease"},{"id":"660","span":{"begin":683,"end":692},"obj":"Disease"},{"id":"661","span":{"begin":917,"end":926},"obj":"Disease"},{"id":"662","span":{"begin":1046,"end":1054},"obj":"Disease"},{"id":"663","span":{"begin":1078,"end":1086},"obj":"Disease"},{"id":"664","span":{"begin":1534,"end":1542},"obj":"Disease"},{"id":"665","span":{"begin":1543,"end":1552},"obj":"Disease"}],"attributes":[{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:C000657245"},{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Gene:3456"},{"id":"A636","pred":"tao:has_database_id","subj":"636","obj":"Gene:22848"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"Gene:59272"},{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"Tax:2697049"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Tax:9606"},{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Tax:9606"},{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Tax:2697049"},{"id":"A642","pred":"tao:has_database_id","subj":"642","obj":"Tax:9606"},{"id":"A643","pred":"tao:has_database_id","subj":"643","obj":"Tax:10090"},{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Tax:9606"},{"id":"A645","pred":"tao:has_database_id","subj":"645","obj":"Tax:9606"},{"id":"A646","pred":"tao:has_database_id","subj":"646","obj":"Tax:2697049"},{"id":"A647","pred":"tao:has_database_id","subj":"647","obj":"MESH:C000606551"},{"id":"A648","pred":"tao:has_database_id","subj":"648","obj":"MESH:C000606551"},{"id":"A649","pred":"tao:has_database_id","subj":"649","obj":"MESH:D002738"},{"id":"A650","pred":"tao:has_database_id","subj":"650","obj":"MESH:C032855"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"MESH:C041747"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"MESH:D012254"},{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"MESH:C053539"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"MESH:C462182"},{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"MESH:D019438"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"MESH:C000596027"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"MESH:C086979"},{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"MESH:D007239"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"MESH:D007239"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"MESH:D007239"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"MESH:C000657245"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"MESH:D007239"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"MESH:C000657245"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T78","span":{"begin":995,"end":1007},"obj":"Body_part"},{"id":"T79","span":{"begin":1203,"end":1211},"obj":"Body_part"},{"id":"T80","span":{"begin":1287,"end":1297},"obj":"Body_part"}],"attributes":[{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":995,"end":1007},"obj":"Body_part"},{"id":"T7","span":{"begin":995,"end":1000},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T186","span":{"begin":41,"end":49},"obj":"Disease"},{"id":"T187","span":{"begin":364,"end":372},"obj":"Disease"},{"id":"T188","span":{"begin":364,"end":368},"obj":"Disease"},{"id":"T189","span":{"begin":520,"end":529},"obj":"Disease"},{"id":"T190","span":{"begin":683,"end":692},"obj":"Disease"},{"id":"T191","span":{"begin":898,"end":906},"obj":"Disease"},{"id":"T192","span":{"begin":898,"end":902},"obj":"Disease"},{"id":"T193","span":{"begin":917,"end":926},"obj":"Disease"},{"id":"T194","span":{"begin":1046,"end":1054},"obj":"Disease"},{"id":"T195","span":{"begin":1249,"end":1257},"obj":"Disease"},{"id":"T196","span":{"begin":1249,"end":1253},"obj":"Disease"},{"id":"T197","span":{"begin":1534,"end":1542},"obj":"Disease"},{"id":"T198","span":{"begin":1543,"end":1552},"obj":"Disease"}],"attributes":[{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A187","pred":"mondo_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A188","pred":"mondo_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A191","pred":"mondo_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A193","pred":"mondo_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A194","pred":"mondo_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A195","pred":"mondo_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A196","pred":"mondo_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A197","pred":"mondo_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A198","pred":"mondo_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T171","span":{"begin":186,"end":188},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T172","span":{"begin":216,"end":219},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T173","span":{"begin":255,"end":260},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T174","span":{"begin":451,"end":453},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T175","span":{"begin":668,"end":674},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T176","span":{"begin":743,"end":745},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T177","span":{"begin":755,"end":757},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T178","span":{"begin":930,"end":936},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T179","span":{"begin":995,"end":1007},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T180","span":{"begin":1153,"end":1154},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T181","span":{"begin":1377,"end":1380},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T182","span":{"begin":1414,"end":1415},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T62","span":{"begin":104,"end":115},"obj":"Chemical"},{"id":"T63","span":{"begin":132,"end":137},"obj":"Chemical"},{"id":"T64","span":{"begin":205,"end":215},"obj":"Chemical"},{"id":"T65","span":{"begin":307,"end":318},"obj":"Chemical"},{"id":"T66","span":{"begin":322,"end":332},"obj":"Chemical"},{"id":"T67","span":{"begin":333,"end":337},"obj":"Chemical"},{"id":"T68","span":{"begin":810,"end":819},"obj":"Chemical"},{"id":"T69","span":{"begin":823,"end":834},"obj":"Chemical"},{"id":"T70","span":{"begin":1298,"end":1305},"obj":"Chemical"}],"attributes":[{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_53000"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":49},"obj":"Sentence"},{"id":"T132","span":{"begin":50,"end":266},"obj":"Sentence"},{"id":"T133","span":{"begin":267,"end":455},"obj":"Sentence"},{"id":"T134","span":{"begin":456,"end":530},"obj":"Sentence"},{"id":"T135","span":{"begin":531,"end":759},"obj":"Sentence"},{"id":"T136","span":{"begin":760,"end":951},"obj":"Sentence"},{"id":"T137","span":{"begin":952,"end":1149},"obj":"Sentence"},{"id":"T138","span":{"begin":1150,"end":1260},"obj":"Sentence"},{"id":"T139","span":{"begin":1261,"end":1369},"obj":"Sentence"},{"id":"T140","span":{"begin":1370,"end":1558},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T542","span":{"begin":41,"end":49},"obj":"SP_7"},{"id":"T543","span":{"begin":104,"end":115},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T544","span":{"begin":126,"end":131},"obj":"NCBITaxon:10239"},{"id":"T545","span":{"begin":132,"end":137},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T546","span":{"begin":162,"end":167},"obj":"NCBITaxon:10239"},{"id":"T547","span":{"begin":205,"end":215},"obj":"DG_28"},{"id":"T548","span":{"begin":255,"end":260},"obj":"NCBITaxon:10239"},{"id":"T549","span":{"begin":267,"end":277},"obj":"DG_28"},{"id":"T550","span":{"begin":307,"end":318},"obj":"DG_10;CHEBI:3638;CHEBI:3638"},{"id":"T551","span":{"begin":322,"end":337},"obj":"PR:000024939"},{"id":"T552","span":{"begin":364,"end":374},"obj":"SP_7"},{"id":"T553","span":{"begin":375,"end":386},"obj":"GO:0006260"},{"id":"T554","span":{"begin":475,"end":481},"obj":"NCBITaxon:10239"},{"id":"T555","span":{"begin":543,"end":555},"obj":"CHEBI:17154;CHEBI:17154"},{"id":"T556","span":{"begin":557,"end":566},"obj":"CHEBI:63580;CHEBI:63580;DG_29"},{"id":"T557","span":{"begin":568,"end":579},"obj":"CHEBI:7956;CHEBI:7956"},{"id":"T558","span":{"begin":581,"end":592},"obj":"CHEBI:119915;CHEBI:119915;DG_17"},{"id":"T559","span":{"begin":594,"end":603},"obj":"DG_30"},{"id":"T560","span":{"begin":605,"end":609},"obj":"PR:000003526"},{"id":"T561","span":{"begin":611,"end":622},"obj":"DG_41"},{"id":"T562","span":{"begin":628,"end":635},"obj":"DG_49"},{"id":"T563","span":{"begin":823,"end":834},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T564","span":{"begin":898,"end":908},"obj":"SP_7"},{"id":"T565","span":{"begin":930,"end":936},"obj":"NCBITaxon:9606"},{"id":"T566","span":{"begin":941,"end":945},"obj":"NCBITaxon:10088"},{"id":"T567","span":{"begin":995,"end":1007},"obj":"UBERON:0001969"},{"id":"T568","span":{"begin":1046,"end":1054},"obj":"SP_7"},{"id":"T569","span":{"begin":1203,"end":1211},"obj":"GO:0042571"},{"id":"T570","span":{"begin":1249,"end":1259},"obj":"SP_7"},{"id":"T571","span":{"begin":1287,"end":1295},"obj":"GO:0042571"},{"id":"T572","span":{"begin":1298,"end":1305},"obj":"BV_9"},{"id":"T573","span":{"begin":1341,"end":1345},"obj":"G_3;PG_10;PR:000003622"},{"id":"T574","span":{"begin":1487,"end":1497},"obj":"GO:0042571"},{"id":"T575","span":{"begin":1534,"end":1542},"obj":"SP_7"},{"id":"T56322","span":{"begin":41,"end":49},"obj":"SP_7"},{"id":"T27276","span":{"begin":104,"end":115},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T5576","span":{"begin":126,"end":131},"obj":"NCBITaxon:10239"},{"id":"T78132","span":{"begin":132,"end":137},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T34797","span":{"begin":162,"end":167},"obj":"NCBITaxon:10239"},{"id":"T81336","span":{"begin":205,"end":215},"obj":"DG_28"},{"id":"T90544","span":{"begin":255,"end":260},"obj":"NCBITaxon:10239"},{"id":"T7656","span":{"begin":267,"end":277},"obj":"DG_28"},{"id":"T83331","span":{"begin":307,"end":318},"obj":"DG_10;CHEBI:3638;CHEBI:3638"},{"id":"T49799","span":{"begin":322,"end":337},"obj":"PR:000024939"},{"id":"T8847","span":{"begin":364,"end":374},"obj":"SP_7"},{"id":"T97023","span":{"begin":375,"end":386},"obj":"GO:0006260"},{"id":"T81907","span":{"begin":475,"end":481},"obj":"NCBITaxon:10239"},{"id":"T18257","span":{"begin":543,"end":555},"obj":"CHEBI:17154;CHEBI:17154"},{"id":"T52332","span":{"begin":557,"end":566},"obj":"CHEBI:63580;CHEBI:63580;DG_29"},{"id":"T47704","span":{"begin":568,"end":579},"obj":"CHEBI:7956;CHEBI:7956"},{"id":"T49574","span":{"begin":581,"end":592},"obj":"CHEBI:119915;CHEBI:119915;DG_17"},{"id":"T61606","span":{"begin":594,"end":603},"obj":"DG_30"},{"id":"T43613","span":{"begin":605,"end":609},"obj":"PR:000003526"},{"id":"T67569","span":{"begin":611,"end":622},"obj":"DG_41"},{"id":"T1403","span":{"begin":628,"end":635},"obj":"DG_49"},{"id":"T10184","span":{"begin":823,"end":834},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T21946","span":{"begin":898,"end":908},"obj":"SP_7"},{"id":"T46433","span":{"begin":930,"end":936},"obj":"NCBITaxon:9606"},{"id":"T30825","span":{"begin":941,"end":945},"obj":"NCBITaxon:10088"},{"id":"T64508","span":{"begin":995,"end":1007},"obj":"UBERON:0001969"},{"id":"T4651","span":{"begin":1046,"end":1054},"obj":"SP_7"},{"id":"T50772","span":{"begin":1203,"end":1211},"obj":"GO:0042571"},{"id":"T19930","span":{"begin":1249,"end":1259},"obj":"SP_7"},{"id":"T75033","span":{"begin":1287,"end":1295},"obj":"GO:0042571"},{"id":"T85523","span":{"begin":1298,"end":1305},"obj":"BV_9"},{"id":"T66326","span":{"begin":1341,"end":1345},"obj":"G_3;PG_10;PR:000003622"},{"id":"T61832","span":{"begin":1487,"end":1497},"obj":"GO:0042571"},{"id":"T75491","span":{"begin":1534,"end":1542},"obj":"SP_7"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"2_test","denotations":[{"id":"32257431-31745213-54950110","span":{"begin":174,"end":176},"obj":"31745213"},{"id":"32257431-29511076-54950111","span":{"begin":262,"end":264},"obj":"29511076"},{"id":"32257431-31924756-54950112","span":{"begin":439,"end":441},"obj":"31924756"},{"id":"32257431-31924756-54950113","span":{"begin":737,"end":739},"obj":"31924756"},{"id":"32257431-31924756-54950114","span":{"begin":947,"end":949},"obj":"31924756"}],"text":"Potential therapeutic strategies against COVID-19\nInitially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}